

## ICMJE DISCLOSURE FORM

**Date:** 11/20/2023

**Your Name:** Aleksander Krag

**Manuscript Title:** Click or tap here to enter text.

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)														
Time frame: Since the initial planning of the work																
<b>1</b>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>														
Time frame: past 36 months																
<b>2</b>	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <td style="width: 50%;">EU Horizon 2020</td> <td style="width: 50%;">Coordinator of Galaxy, EU funded under grant agreement No 668031</td> </tr> <tr> <td>EU Horizon 2020</td> <td>PI in LiverScreen, EU funded under grant agreement No 847989</td> </tr> <tr> <td>EU Horizon 2020</td> <td>PI in MicrobPredict, EU funded under grant agreement No 825694.</td> </tr> <tr> <td>EU Horizon 2020</td> <td>PI in IHMCSA, EU funded under grant agreement No 964590</td> </tr> <tr> <td>Novo Nordisk Foundation</td> <td>PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation</td> </tr> <tr> <td>Innovationfund Denmark</td> <td>Research funding, Innoexplorer</td> </tr> <tr> <td>Danish National Research Foundation</td> <td>PI in ATLAS, Centre of Excellence</td> </tr> </table>	EU Horizon 2020	Coordinator of Galaxy, EU funded under grant agreement No 668031	EU Horizon 2020	PI in LiverScreen, EU funded under grant agreement No 847989	EU Horizon 2020	PI in MicrobPredict, EU funded under grant agreement No 825694.	EU Horizon 2020	PI in IHMCSA, EU funded under grant agreement No 964590	Novo Nordisk Foundation	PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation	Innovationfund Denmark	Research funding, Innoexplorer	Danish National Research Foundation	PI in ATLAS, Centre of Excellence
EU Horizon 2020	Coordinator of Galaxy, EU funded under grant agreement No 668031															
EU Horizon 2020	PI in LiverScreen, EU funded under grant agreement No 847989															
EU Horizon 2020	PI in MicrobPredict, EU funded under grant agreement No 825694.															
EU Horizon 2020	PI in IHMCSA, EU funded under grant agreement No 964590															
Novo Nordisk Foundation	PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation															
Innovationfund Denmark	Research funding, Innoexplorer															
Danish National Research Foundation	PI in ATLAS, Centre of Excellence															

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		<div>Region of Southern Denmark</div> <div>AstraZeneca</div>	<div>Center grant for Elite Research Centre FLASH</div> <div>Prevalence and severity of NAFLD in Denmark</div>
3	Royalties or licenses	<input type="checkbox"/> <b>None</b>	
		<div>Gyldendal</div> <div></div> <div></div>	<div>Medicinsk compendium, coauthor (Textbook of internal medicine)</div> <div></div> <div></div>
4	Consulting fees	<input checked="" type="checkbox"/> <b>None</b>	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> <b>None</b>	
		<div>Norgine</div> <div>Siemens</div> <div>Nordic Bioscience</div> <div>NovoNordisk</div>	<div>Lectures 2019, 2020</div> <div>Lectures, speaker's bureau 2019, 2020</div> <div>Lecture 2021</div> <div>Lecture 2023</div>
6	Payment for expert testimony	<input checked="" type="checkbox"/> <b>None</b>	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> <b>None</b>	
8	Patents planned, issued or pending	<input type="checkbox"/> <b>None</b>	
		<div>Region of Southern Denmark</div> <div>University of Southern Denmark</div> <div></div>	<div>Biomarker - pending/planned</div> <div>Biomarker- pending/planned</div> <div></div>
9	Participation on a Data Safety	<input type="checkbox"/> <b>None</b>	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
	Monitoring Board or Advisory Board	<table border="1"> <tr><td>Norgine</td></tr> <tr><td>Siemens</td></tr> <tr><td>Novo Nordisk</td></tr> <tr><td>B&amp;I</td></tr> </table>	Norgine	Siemens	Novo Nordisk	B&I	<table border="1"> <tr><td>Advisory board meeting 2020</td></tr> <tr><td>Advisory board meeting 2019, 2020, 2023</td></tr> <tr><td>Advisory Board 2023</td></tr> <tr><td>Advisory Board 2023</td></tr> </table>	Advisory board meeting 2020	Advisory board meeting 2019, 2020, 2023	Advisory Board 2023	Advisory Board 2023
Norgine											
Siemens											
Novo Nordisk											
B&I											
Advisory board meeting 2020											
Advisory board meeting 2019, 2020, 2023											
Advisory Board 2023											
Advisory Board 2023											
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> <b>None</b> <table border="1"> <tr> <td>Secretary General European Association for the Study of The Liver (EASL) 2023-2025</td> <td>Non for profit organization</td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Secretary General European Association for the Study of The Liver (EASL) 2023-2025	Non for profit organization						
Secretary General European Association for the Study of The Liver (EASL) 2023-2025	Non for profit organization										
11	Stock or stock options	<input checked="" type="checkbox"/> <b>None</b> <table border="1"> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>									
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> <b>None</b> <table border="1"> <tr> <td>Norgine</td> <td>Rifaximin for an investigator-initiated study, part of Galaxy, an EU funded project under grant agreement No 668031</td> </tr> <tr> <td>Siemens</td> <td>ELF test for an investigator-initiated study</td> </tr> <tr> <td>Echosence</td> <td>Fibroscan for an investigator-initiated study, part of LiverScreen, an EU funded project under grant agreement No 847989</td> </tr> <tr> <td>NordicBioscience</td> <td>ECM markers for investigator-initiated studies</td> </tr> </table>		Norgine	Rifaximin for an investigator-initiated study, part of Galaxy, an EU funded project under grant agreement No 668031	Siemens	ELF test for an investigator-initiated study	Echosence	Fibroscan for an investigator-initiated study, part of LiverScreen, an EU funded project under grant agreement No 847989	NordicBioscience	ECM markers for investigator-initiated studies
Norgine	Rifaximin for an investigator-initiated study, part of Galaxy, an EU funded project under grant agreement No 668031										
Siemens	ELF test for an investigator-initiated study										
Echosence	Fibroscan for an investigator-initiated study, part of LiverScreen, an EU funded project under grant agreement No 847989										
NordicBioscience	ECM markers for investigator-initiated studies										
13	Other financial or non-financial interests	<input type="checkbox"/> <b>None</b> <table border="1"> <tr> <td>Board member and co-founder Evido</td> <td> </td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Board member and co-founder Evido							
Board member and co-founder Evido											
<p><b>Please place an "X" next to the following statement to indicate your agreement:</b></p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>											